Cargando…
Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis
Background: There are several selective serotonin reuptake inhibitor (SSRI) antidepressants currently used to treat binge eating disorder (BED), but the efficacy and acceptability of these antidepressants are still controversial. Therefore, we designed a network meta-analysis (NMA) to compare the ef...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486087/ https://www.ncbi.nlm.nih.gov/pubmed/36147335 http://dx.doi.org/10.3389/fphar.2022.949823 |
_version_ | 1784792200257732608 |
---|---|
author | Duan, Hanying Zhu, Lijun Li, Min Zhang, Xinyue Zhang, Beilin Fang, Shaokuan |
author_facet | Duan, Hanying Zhu, Lijun Li, Min Zhang, Xinyue Zhang, Beilin Fang, Shaokuan |
author_sort | Duan, Hanying |
collection | PubMed |
description | Background: There are several selective serotonin reuptake inhibitor (SSRI) antidepressants currently used to treat binge eating disorder (BED), but the efficacy and acceptability of these antidepressants are still controversial. Therefore, we designed a network meta-analysis (NMA) to compare the efficacy and acceptability of different SSRI antidepressants for the treatment of BED. Methods: Four databases including PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched for the eligible randomized controlled trials (RCTs) for the treatment of patients with BED. The analysis was performed with Stata16 software. Results: 9 RCTs were included in this NMA. The results of the study showed that compared with placebo, sertraline and fluoxetine could significantly reduce the frequency of binge eating. Fluoxetine was shown to be the drug with the greatest reduction in Hamilton Rating Scale for Depression (HAMD) score. Besides, all SSRI antidepressants were ineffective in losing weight. In addition, all the investigated antidepressants were found to be well acceptable in regards to the acceptability reflected by the dropout rate. Conclusion: As far as both efficacy and acceptability were concerned, fluoxetine might be the best choice. |
format | Online Article Text |
id | pubmed-9486087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94860872022-09-21 Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis Duan, Hanying Zhu, Lijun Li, Min Zhang, Xinyue Zhang, Beilin Fang, Shaokuan Front Pharmacol Pharmacology Background: There are several selective serotonin reuptake inhibitor (SSRI) antidepressants currently used to treat binge eating disorder (BED), but the efficacy and acceptability of these antidepressants are still controversial. Therefore, we designed a network meta-analysis (NMA) to compare the efficacy and acceptability of different SSRI antidepressants for the treatment of BED. Methods: Four databases including PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched for the eligible randomized controlled trials (RCTs) for the treatment of patients with BED. The analysis was performed with Stata16 software. Results: 9 RCTs were included in this NMA. The results of the study showed that compared with placebo, sertraline and fluoxetine could significantly reduce the frequency of binge eating. Fluoxetine was shown to be the drug with the greatest reduction in Hamilton Rating Scale for Depression (HAMD) score. Besides, all SSRI antidepressants were ineffective in losing weight. In addition, all the investigated antidepressants were found to be well acceptable in regards to the acceptability reflected by the dropout rate. Conclusion: As far as both efficacy and acceptability were concerned, fluoxetine might be the best choice. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9486087/ /pubmed/36147335 http://dx.doi.org/10.3389/fphar.2022.949823 Text en Copyright © 2022 Duan, Zhu, Li, Zhang, Zhang and Fang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Duan, Hanying Zhu, Lijun Li, Min Zhang, Xinyue Zhang, Beilin Fang, Shaokuan Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title | Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title_full | Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title_fullStr | Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title_full_unstemmed | Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title_short | Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis |
title_sort | comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: a network meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486087/ https://www.ncbi.nlm.nih.gov/pubmed/36147335 http://dx.doi.org/10.3389/fphar.2022.949823 |
work_keys_str_mv | AT duanhanying comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis AT zhulijun comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis AT limin comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis AT zhangxinyue comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis AT zhangbeilin comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis AT fangshaokuan comparativeefficacyandacceptabilityofselectiveserotoninreuptakeinhibitorantidepressantsforbingeeatingdisorderanetworkmetaanalysis |